Login to Your Account

Phase III fries Dipexium as foot ulcer no-pulser sinks dream of cream

By Randy Osborne
Staff Writer

Tuesday, October 25, 2016

Dipexium Pharmaceuticals Inc. is still sorting through data from a pair of identical phase III trials, but top-line findings in mild infections of diabetic foot ulcers with the company's lead – and only – product did nothing to encourage investors, and shares tumbled 78 percent.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription